See how AbbVie Inc. and Vanguard S&P 500 ETF differ across market data and performance, so you can decide which asset best fits your strategy.
$254.49
NYSE
AbbVie Inc. is a pharmaceutical company with significant exposure to immunology through Humira, Skyrizi, and Rinvoq, and to oncology through Imbruvica and Venclexta. The company was spun off from Abbott in early 2013. Its 2020 acquisition of Allergan expanded its portfolio with additional products in aesthetics, including Botox. In 2024, AbbVie further strengthened its business through the acquisitions of Cerevel in neuroscience and ImmunoGen in oncology.
Vanguard S&P 500 ETF is an exchange-traded fund that gives investors diversified exposure to large-cap U.S. companies in the S&P 500 Index. It is designed to track or represent a basket of publicly traded securities rather than a single company, making it useful for portfolio allocation, regional exposure, and thematic positioning. Its performance depends on the underlying holdings, sector and country weights, currency movements where relevant, fund expenses, and broader equity-market conditions.